Arena Stock Analysis

ARNA -  USA Stock  

USD 89.89  0.06  0.07%

The current price rise of Arena Pharmaceuticals could raise concerns from investors as the firm it trading at a share price of 89.89 on 918,806 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 90 days investing horizon is currently 10.47. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Arena Pharmaceuticals partners.
Please continue to Trending Equities.

Arena Stock Analysis 

 
Refresh
The Arena Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Arena Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Arena Stock analysis module also helps to analyze the Arena Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Arena Stock Analysis Notes

About 93.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.46. Arena Pharmaceuticals recorded a loss per share of 9.72. The entity had not issued any dividends in recent years. The firm had a split on the 19th of June 2017. Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. Arena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 363 people. For more info on Arena Pharmaceuticals please contact Amit Munshi at 858 453-7200 or go to www.arenapharm.com.

Arena Pharmaceuticals Quarterly Cost of Revenue

0.0Share

Arena Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Arena Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Arena Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Arena Pharmaceuticals is way too risky over 90 days horizon
Arena Pharmaceuticals appears to be risky and price may revert if volatility continues
Arena Pharmaceuticals is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 37 K. Net Loss for the year was (582.99 M) with loss before overhead, payroll, taxes, and interest of (323.42 M).
Arena Pharmaceuticals currently holds about 771.67 M in cash with (437.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.58.
Arena Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Over 93.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Apollon Formularies plc Announces CEO Review of 2021 - Yahoo Finance

Arena Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Arena Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arena Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report22nd of February 2022
Next Earnings Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End22nd of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Arena Largest EPS Surprises

Earnings surprises can significantly impact Arena Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-03-02
2014-12-31-0.12-0.15-0.0325 
2015-05-11
2015-03-31-0.14-0.10.0428 
2001-04-17
2001-03-310.450.50.0511 
View All Earnings Estimates

Arena Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Arena Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Arena Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Arena Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
7th of January 2022
Other Events
View
13th of December 2021
Financial Statements and Exhibits. Other Events. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Entry into a Material Definitive Agreement
View
4th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
17th of June 2021
Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Arena Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 5.53 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arena Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Arena Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Arena Profitablity

Arena Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Arena Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Arena Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Arena Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Arena Pharmaceuticals' profitability requires more research than a typical breakdown of Arena Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(34.18) (36.88) 
Return on Average Assets(0.38) (0.41) 
Return on Average Equity(0.42) (0.45) 
Return on Invested Capital(0.53) (0.57) 
Return on Sales-1.1 K-1.2 K

Management Efficiency

The entity has return on total asset (ROA) of (30.79) % which means that it has lost $30.79 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (59.17) %, meaning that it created substantial loss on money invested by shareholders. Arena Pharmaceuticals management efficiency ratios could be used to measure how well arena pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 25, 2022, Return on Investment is expected to decline to -36.88. In addition to that, Return on Average Assets is expected to decline to -0.41. Arena Pharmaceuticals Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 1.37 Billion. The current year Current Assets is expected to grow to about 1.4 B, whereas Tax Assets are forecasted to decline to about 98.7 M.
Last ReportedProjected for 2022
Book Value per Share 22.69  24.48 
Enterprise Value over EBIT(11.50) (12.41) 
Enterprise Value over EBITDA(11.77) (12.69) 
Price to Book Value 3.72  3.82 
Tangible Assets Book Value per Share 25.00  21.15 
Enterprise Value4.7 BB
Tangible Asset Value1.4 B1.5 B

Technical Drivers

As of the 25th of January, Arena Pharmaceuticals shows the risk adjusted performance of 0.084, and Mean Deviation of 3.13. Arena Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Arena Pharmaceuticals, which can be compared to its rivals. Please confirm Arena Pharmaceuticals downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Arena Pharmaceuticals is priced correctly, providing market reflects its regular price of 89.89 per share. Given that Arena Pharmaceuticals has jensen alpha of 0.8649, we suggest you to validate Arena Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Arena Pharmaceuticals Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Arena Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Arena Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Arena Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arena Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arena Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arena Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Manion Douglas J over two weeks ago via Macroaxis 
Acquisition by Manion Douglas J of 21462 shares of Arena Pharmaceuticals subject to Rule 16b-3
Manion Douglas J over three months ago via Macroaxis 
Acquisition by Manion Douglas J of 15200 shares of Arena Pharmaceuticals subject to Rule 16b-3
Schoch Steven J over six months ago via Macroaxis 
Acquisition by Schoch Steven J of 7202 shares of Arena Pharmaceuticals subject to Rule 16b-3
Schmidt Joan over six months ago via Macroaxis 
Exercise or conversion by Schmidt Joan of 12600 shares of Arena Pharmaceuticals subject to Rule 16b-3
Schmidt Joan over six months ago via Macroaxis 
Acquisition by Schmidt Joan of 15200 shares of Arena Pharmaceuticals subject to Rule 16b-3
Robert Lisicki over six months ago via Macroaxis 
Exercise or conversion by Robert Lisicki of 17500 shares of Arena Pharmaceuticals subject to Rule 16b-3
Jayson Dallas over a year ago via Macroaxis 
Sale by Jayson Dallas of 1327 shares of Arena Pharmaceuticals
Amit Munshi over a year ago via Macroaxis 
Sale by Amit Munshi of 5396 shares of Arena Pharmaceuticals
Robert Lisicki over a year ago via Macroaxis 
Exercise or conversion by Robert Lisicki of 12600 shares of Arena Pharmaceuticals subject to Rule 16b-3
Jayson Dallas over a year ago via Macroaxis 
Purchase by Jayson Dallas of tradable shares of Arena Pharmaceuticals
Jayson Dallas over a year ago via Macroaxis 
Purchase by Jayson Dallas of tradable shares of Arena Pharmaceuticals
Robert Lisicki over a year ago via Macroaxis 
Sale by Robert Lisicki of 550 shares of Arena Pharmaceuticals

Arena Pharmaceuticals Technical and Predictive Indicators

Arena Pharmaceuticals Forecast Models

Arena Pharmaceuticals time-series forecasting models is one of many Arena Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arena Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Arena Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arena Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arena shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Arena Pharmaceuticals. By using and applying Arena Stock analysis, traders can create a robust methodology for identifying Arena entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 53.88  58.13 
EBITDA Margin 0.74  0.79 
Gross Margin 1.15  1.12 
Profit Margin 0.57  0.62 
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. Arena Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 363 people.

Current Arena Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arena analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arena analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
96.38Hold8Odds
Arena Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Arena analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Arena stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Arena Pharmaceuticals, talking to its executives and customers, or listening to Arena conference calls.
Arena Analyst Advice Details

Arena Stock Analysis Indicators

Arena Pharmaceuticals stock analysis indicators help investors evaluate how Arena Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arena Pharmaceuticals shares will generate the highest return on investment. By understating and applying Arena Pharmaceuticals stock analysis, traders can identify Arena Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio14.47
Fifty Two Week Low45.50
Shares Short Prior Month1.87M
Average Daily Volume Last 10 Day1.63M
Average Daily Volume In Three Month1.38M
Shares Percent Shares Out2.48%
Short Percent Of Float2.88%
Forward Price Earnings-10.65
Float Shares57.77M
Fifty Two Week High94.23
Enterprise Value To Ebitda-9.30
Fifty Day Average76.95
Two Hundred Day Average65.43
Enterprise Value To Revenue133,816.16
Please continue to Trending Equities. Note that the Arena Pharmaceuticals information on this page should be used as a complementary analysis to other Arena Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Arena Stock analysis

When running Arena Pharmaceuticals price analysis, check to measure Arena Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arena Pharmaceuticals is operating at the current time. Most of Arena Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arena Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Arena Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arena Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Arena Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arena Pharmaceuticals. If investors know Arena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arena Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Arena Pharmaceuticals is measured differently than its book value, which is the value of Arena that is recorded on the company's balance sheet. Investors also form their own opinion of Arena Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arena Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arena Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arena Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arena Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Arena Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arena Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.